Ivaltinostat

DRUG2 trials

Sponsors

CG Pharmaceuticals, Inc, Machaon Biotherapeutics, Inc.

Conditions

FibrosisHematologic MalignancyMetastatic Pancreatic AdenocarcinomaSolid Tumor

Phase 1

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Active, not recruitingNCT05249101

CG Pharmaceuticals, IncMetastatic Pancreatic Adenocarcinoma

Start: 2022-08-15End: 2026-07-31Target: 70Updated: 2025-12-19

Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule

Machaon Biotherapeutics, Inc.Fibrosis, Hematologic Malignancy, Solid Tumor

Start: 2023-03-09End: 2023-12-31Updated: 2023-10-23

Related Papers

Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study.

Journal of Clinical Oncology2025-01-27

A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).

Journal of Clinical Oncology2024-06-01

Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).

Journal of Clinical Oncology2024-01-20